SJSima Jeha

Sima Jeha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sima Jeha has a total of 517 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High‐Dimensional Mediation Analysis With Network Mediators: Applications to Pediatric Acute Lymphoblastic Leukemia

    by Jade Xiaoqing Wang, Zhao‐Hua Lu, Wilburn E. Reddick, Heather M. Conklin, John O. Glass, Lisa Jacola, Arzu Onar‐Thomas, Sima Jeha, Cheng Cheng, Xiang Zhou, et al.

    Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, with survivors frequently experiencing long‐term neurocognitive morbidities. Here, we utilize the TOTXVI clinical trial data to elucidate the mechanisms underlying treatment‐related neurocognitive side effects in pediatric ALL patients by incorporating brain connectivity network data. To enable such analysis, we propose a high‐dimensional mediation analysis method with a novel network mediation structural shrinkage (NMSS) prior, which is particularly suited for analyzing high‐dimensional brain structural connectivity network data that serve as mediators. Our method is capable of addressing the structural dependencies of brain connectivity networks including sparsity, effective degrees of nodes, and modularity, yielding accurate estimates of the high‐dimensional coefficients and mediation effects. We demonstrate the effectiveness and superiority of the proposed NMSS method through simulation studies and apply it to the TOTXVI data, revealing significant mediation effects of brain connectivity on visual processing speed directed by IT intensity. The findings shed light on the potential of targeted interventions to mitigate neurocognitive deficits in pediatric ALL survivors.

  • Open Access

    Crossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative

    by Khaled Ghanem, Ayman Tawil, Sara Sinno, Teresa Santiago, Omar El Khatib, Mohamad Harajli, Rihab Nasr, Ghazi Zaatari, Suzan Alsakka, Rasha Alyoussef, et al.

    PURPOSE: Barriers to accurate histopathologic diagnosis in lower middle-income countries (LMIC) undermine appropriate patient outcomes. We report the results of a regional LMIC twinning initiative, with the support of a high-income country institution, for building capacity in histopathologic diagnosis of pediatric cancers. METHODS: A pathology review initiative was conducted between July 2019 and June 2024, where 6 cases per month from a developing center in Syria were reviewed regionally at an established center in Lebanon. Cases for which no diagnosis could be made were sent to St Jude Children's Research Hospital for a third read. Monthly meetings were held to discuss diagnoses and reasons for discrepancies. Biannual capacity building meetings were held to discuss opportunities for improvement. RESULTS: A total of 81 cases were reviewed, of which 44 were extracranial solid tumors, 29 brain tumors, and eight hematologic malignancies. Of these, 77 were of sufficient quality, and seven were sent for a third read. Among the 70 cases with a regional final diagnosis, 53 (76%) were concordant, 12 (17%) had major discrepancies, and 5 (7%) had minor discrepancies. Reasons for discrepancies were morphologic interpretation (n = 9, 52%), combined interpretation and immunohistochemistry (n = 4, 24%), and unavailability of specific immunostains (n = 4, 24%). The highest number of discrepancies were in brain tumors, followed by solid tumors. Several opportunities were identified for local improvement and patient safety, including focused pathologist training and specific assay development. CONCLUSION: Our results demonstrate the feasibility of a supported regional south-south twinning initiative in building capacity for accurate pediatric oncology histopathology. Beyond knowledge transfer, it revealed areas for local improvement including specific local laboratory processes, technical training, and local reporting tools.

  • Navigating the Planning and Initiation of a First Prospective Clinical Trial Through a Regional Pediatric Oncology Consortium Within the Middle East, Africa, and Asia—A Roadmap

    by Ruzanna Papyan, Farah Ghamloush, Iman Sidhom, Asim Belgaumi, Rihab Nasr, Iyad Sultan, Gevorg Tamamyan, Venkatraman Radhakrishnan, Carlos Rodriguez‐Galindo, Sima Jeha, et al.

    Background: Prospective pediatric oncology clinical trials remain scarce across low‐ and middle‐income countries (LMICs). We developed the first multicountry prospective clinical trial within the Pediatric Oncology East and Mediterranean (POEM) group. Localized osteosarcoma was selected due to heterogeneous real‐world management, including alternative regimens in settings where methotrexate administration is not feasible. This descriptive report details the feasibility of a regionally coordinated, resource‐adapted clinical trial across diverse LMIC settings. Methods: We describe the planning, capacity assessment, training, governance, and activation of POEM‐OS, a pragmatic two‐arm prospective cohort study evaluating MAP‐ and OS99‐based therapy for localized osteosarcoma. Preparation included a structured capacity‐mapping exercise across regional centers to assess clinical resources, research, and regulatory structures. The approach also encompassed designing a training program and communication through a structured study coordination team. Results: A total of 27 centers from 10 countries expressed intent to participate. A 12‐week virtual training curriculum was implemented for principal investigator and clinical research coordinator dyads, followed by an in‐person regional workshop. Eventually, 21 centers (8 countries) proceeded to study activation. Major barriers included heterogeneity in chemotherapy administration, high staff turnover, and variability in timelines to study‐agreement execution. Adaptive solutions included permanently accessible online training modules, simplified chemotherapy dosing, and harmonized toxicity grading. Centralized REDCap platforms enabled regional data sharing. By February 2026, the study had opened at 16 centers, with 21 patients enrolled. Conclusion: POEM‐OS demonstrates that a regionally directed, resource‐adapted clinical trial platform is feasible across diverse LMIC settings and establishes a foundation for sustainable regional clinical research infrastructure.

  • Clinical Research Capacity Building in Pediatric Oncology in Resource-Limited Settings: Application and Early Results of Regional Educational Workshops

    by Raya Saab, Rihab Nasr, Iman Sidhom, Asim Belgaumi, Meenakshi Devidas, Paula Naidu, Vaskar Saha, Iyad Sultan, Paola Friedrich, Mariam Fanous, et al.

    PURPOSE: The global need for training in clinical research is substantial, particularly in resource-limited settings. We describe an international collaboration to build capacity in clinical research skills through a semi-personalized curriculum. METHODS: Five sequential workshops (2020-2025) combined online modules with on-site, project-based learning. The curriculum across workshops included research project planning, proposal writing, and manuscript publishing. Topics included fundamentals of clinical study design, data registries, statistical considerations, research ethics, and scientific writing. At registration, applicants submitted an abstract for further development. An average of 35 applicants per workshop were selected. Participants' experiences were evaluated through postworkshop surveys. RESULTS: Participants across the workshops presented from 17 countries and seven disciplines, with the majority being physicians (66%) and nurses (16%). During each 2.5-day workshop, participants refined their abstracts with structured guidance and shared their work in a 10-minute presentation. Workshop 1 used a group-based model where each group developed one common Workshop 2 focused on quality improvement research; each group worked on preselected mock concepts through a structured learning exercise. Workshops 3 and 4 involved individualized learning, with each participant developing their own abstract into a study proposal. Workshop 5 focused on scientific writing, guiding participants to develop their abstracts into a manuscript outline. Surveys after each workshop consistently demonstrated a high level of satisfaction and perceived gain in knowledge and skill. CONCLUSION: These workshops effectively engaged trainees with various levels of clinical research training and imparted skills for research planning and manuscript writing. Future iterations will include thematic workshops including advanced statistical methods. Combining asynchronous learning modules with on-site, project-based training can be implemented across other regions and specialties in context-relevant settings.

  • Open Access

    Supplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    A multi-national consortium of γδ T-ALL study.

  • Open Access

    Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.

  • Open Access

    Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.

  • Open Access

    Supplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    The genomic features of “Chromosome gains” and “TLX3” subtypes.

  • Open Access

    Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    The gene expression profiles of γδ T-ALL.

  • Open Access

    Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

    by Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, Ilaria Iacobucci, Petri Pölönen, Qingsong Gao, Elizabeth D. Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, et al.

    Compounds used in single-dose (10uM) drug screening.